Uppsala University Hospital
Uppsala, Sweden
NCT Number: NCT05783830
This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy subjects.
Looking for future studies?
Notify Me18 year–65 year
Male
Interventional
Early Phase 1
Uppsala, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IV injection 100 mcg
Time frame: 24 hours
a pharmacokinetic measure of the amount of study medication present in the blood
Time frame: 96 hours
a pharmacokinetic measure of the amount of study medication present in the blood
Time frame: 24 hours
a pharmacokinetic measure of the time it takes for the study drug to be eliminated from the blood
Time frame: 24 hours
a pharmacokinetic measure of the time it takes for the study drug to be eliminated from the blood
Time frame: 24 hours
a theoretical estimate of how much of the study drug that the body may contain
Time frame: 5 days
how many participants have reported a drug related advers event
Time frame: 5 days
how many participants have had any clinically significant changes in vital signs
Time frame: 5 days
how many participants have had study drug related changes to cardiac function
Time frame: 5 days
how many participants have had study drug related changes in laboratory test analyses
AlzeCure Pharma
Industry
A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05077631
Alzheimer Disease, Brain Diseases
Uppsala, Sweden
View Trial DetailsNCT05077501
Alzheimer Disease, Brain Diseases
Uppsala, Sweden
View Trial DetailsNCT07572565
Alzheimer Disease, Brain Diseases
View Trial DetailsNCT05886114
Alzheimer Disease, Brain Diseases
Hangzhou, Zhejiang, China
View Trial Details